P
Paul J. van Diest
Researcher at Utrecht University
Publications - 514
Citations - 22750
Paul J. van Diest is an academic researcher from Utrecht University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 70, co-authored 459 publications receiving 18892 citations. Previous affiliations of Paul J. van Diest include University Medical Center Utrecht & VU University Medical Center.
Papers
More filters
Journal Article
Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases.
Niels Smakman,Onno Kranenburg,Jan M. Vogten,Alexander L. A. Bloemendaal,Paul J. van Diest,Inne H.M. Borel Rinkes +5 more
TL;DR: The high levels of COX-2 enzyme and prostaglandin production in C26 CRC cells are primarily caused by the presence of endogenous mutant KRAS(D12), which affects the tumoral rather than the vascular compartment during the early stages of C26 liver metastasis outgrowth.
Journal ArticleDOI
Whole slide images for primary diagnostics of urinary system pathology: a feasibility study
Shaimaa Al-Janabi,André Huisman,Geertruida N. Jonges,Fiebo J.W. ten Kate,Roel Goldschmeding,Paul J. van Diest +5 more
TL;DR: Primary diagnostics of urinary tract specimens can be reliably done on WSI, and improvements of image resolution may help to increase diagnostic accuracy and WSI acceptance in routine pathology.
Journal ArticleDOI
A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity.
Inge Ubink,Sjoerd G. Elias,Cathy B. Moelans,Miangela M. Lacle,Wilhelmina M U van Grevenstein,Paul J. van Diest,Inne H.M. Borel Rinkes,Onno Kranenburg +7 more
TL;DR: The CMS4 RT-qPCR test is a promising clinical tool for selecting individual patients for CMS4-subtype-targeted therapy and has excellent calibration and approximately 80% overall net benefit over a large threshold range.
Journal ArticleDOI
Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers.
Jan P. A. Baak,Jan P. A. Baak,Cecile Colpaert,Paul J. van Diest,Emiel A. M. Janssen,Bianca van Diermen,Eliza Albernaz,Peter B. Vermeulen,Eric Van Marck +8 more
TL;DR: The FF may be important as it has additional prognostic value to the MAI in the small subgroup of invasive ductal or mixed-ductal breast cancer patients with combined MAI < 10 and an FF > 1/3 of the tumour area.
Journal ArticleDOI
T cell infiltration and MHC I and II expression in the presence of tumor antigens : An immunohistochemical study in patients with serous epithelial ovarian cancer
Hans W. Nijman,Paul J. van Diest,Ria J.J. Poort-Keesom,Silvia von Mensdorff-Pouilly,Rob A. Verstraeten,Alain Kummer,Chris J.L.M. Meijer,Cornelis J. M. Melief,Jo Hilgers,Peter Kenemans +9 more
TL;DR: It is found that granzyme-B, TIA-1 and CD45RO+ T cells are present in the tumor biopsies, increasing this number by immunotherapy may be beneficial, and the immune escape mechanism by MHC class I and beta2m downregulation seems to be of minor importance.